Fig. 1A




Fig. 1B

Human Aggrus/podoplanin amino acid sequence

GenBank accession No. AB127958.1 or AF390106

```
1   MWKVSALLFV  LGSASLWVLA  EGASTGQPED
                                45  48
31  DTETTGLEGG  VAMPGAEDDV  VTPGTSEDRY
    PLAG1       PLAG2        PLAG3
61  KSGLTTLVAT  SVNSVTGIRI  EDLPTSESTV
91  HAQEQSPSAT  ASNVATSHST  EKVDGDTQTT
121 VEKDGLSTVT  LVGIIVGVLL  AIGFIGGIIV
151 VVMRKMSGRY SP
```

Fig. 2A



Number of cells
CHO/Aggrus-WT
CHO/Aggrus-D48E
CHO/Aggrus-D48N
CHO/Aggrus-D48A
Aggrus expression (D2-40)
CLEC-2 binding

Fig. 2B




Aggregation rate (%)
Incubation time (min)
CHO/Aggrus-WT
CHO/Aggrus-D48A
CHO/mock

Fig. 3A



species	accession1	accession2	
Homo_sapiens	gi54792056	NP_006465	human
Pan_paniscus	gi397469333	XP_003806315.1	bonobo
Macaca_mulatta	gi297282234	XP_001106933.2	rhesus monkey
Sus_scrofa	gi545833678	XP_005665074.1	pig
Physeter_catodon	gi593716887	XP_007104886.1	sperm whale
Canis_lupus_familiaris	gi50978994	NP_001003220.1	canine
Myotis_brandtii	gi554558224	XP_005873518.1	bat
Bos_taurus	gi75677538	NP_001028292.1	bovine
Rattus_norvegicus	gi564353955	XP_006239400.1	rat
Mus_musculus	gi113462005	NP_034459.2	mouse

Fig. 3B

PLAG consensus: E D X X V T P G

PLAG1 29-E D D T E T T G-36
PLAG2 38-E G G V A M P G-45
PLAG3 47-E D D V V T P G-54
PLAG4 81-E D L – P T S E-87

Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4E




Fig. 4D




Fig. 5A




Fig. 5B




Fig. 5C




Fig. 6A



Number of cells
CHO/Aggrus-WT
CHO/Aggrus-E47A
CHO/Aggrus-D48A
CHO/Aggrus-T52A
Aggrusexpression (D2-40)
CLEC-2 binding
PLAG3 domain
47- EDDVVT -52

Fig. 6B



CHO/Aggrus-E81A
CHO/Aggrus-D82A
CHO/Aggrus-T85A
Aggrus expression (D2-40)
CLEC-2 binding
PLAG4 domain
81- EDLPT -85

Fig. 7A





Fig. 7B



	ka	kd	KD (M)
PG4D1	$3x10^4$	$\leqq 10^{-5}$	$\leqq 3x10^{-10}$
PG4D2	$3x10^4$	$\leqq 10^{-5}$	$\leqq 3x10^{-10}$

Fig. 7C




Fig. 8A




Fig. 8B




Fig. 8C




Fig. 8D




Fig. 9A



Aggrus-CLEC-2 binding
(% of no IgG control)
125
100
75
50
25
0
10
100
1000
10000
IgG concentration (ng/mL)
Control IgG1
Control IgG2a
MS-1
PG4D1
PG4D2

Fig. 9B



Aggrus-CLEC-2 binding
(% of no IgG control)
150
100
50
0
1
10
100
1000
10000
IgG concentration (ng/mL)
MS-1
6G42A4
9D62D6

Fig. 10A




Fig. 10B




Fig. 10C




Fig. 11A




Fig. 11B




Fig. 12A




Fig. 12B




Fig. 13A




Fig. 13B




Fig. 14A




Fig. 14B




Fig. 15




Fig. 16



Tumor volume (mm3)
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
35
40
Days after antibody inoculation
Control IgG2a
(200 µg/mouse)
PG4D2 (100 µg/mouse)
MS-1 (100 µg/mouse)
PG4D2 + MS-1
(100 µg each/mouse)

Fig. 17A




Fig. 17B




Fig. 18A




Fig. 18B

